264 related articles for article (PubMed ID: 34329939)
1. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
Perez-Fidalgo JA; Cortés A; Guerra E; García Y; Iglesias M; Bohn Sarmiento U; Calvo García E; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
ESMO Open; 2021 Aug; 6(4):100212. PubMed ID: 34329939
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
Perez-Fidalgo JA; Guerra E; García Y; Iglesias M; Hernández-Sosa M; Estevez-García P; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
Int J Gynecol Cancer; 2023 Jun; 33(6):929-936. PubMed ID: 36759001
[TBL] [Abstract][Full Text] [Related]
3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
Lee YJ; Seol A; Lee M; Kim JW; Kim HS; Kim K; Suh DH; Kim S; Kim SW; Lee JY
In Vivo; 2022; 36(4):1949-1958. PubMed ID: 35738633
[TBL] [Abstract][Full Text] [Related]
5. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel BJ; Buss MK; Nattam SR; Hurteau J; Luo W; Curtis J; Whalen C; Kohn EC; Ivy SP; Matulonis UA
Ann Oncol; 2019 Apr; 30(4):551-557. PubMed ID: 30753272
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of chemotherapy according to
Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
[TBL] [Abstract][Full Text] [Related]
8. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
[TBL] [Abstract][Full Text] [Related]
9. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B
J Clin Oncol; 2012 Feb; 30(4):372-9. PubMed ID: 22203755
[TBL] [Abstract][Full Text] [Related]
10. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
11. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
12. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
13. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
[TBL] [Abstract][Full Text] [Related]
14. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
15. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
16. Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
Vanderstichele A; Loverix L; Busschaert P; Van Nieuwenhuysen E; Han SN; Concin N; Callewaert T; Olbrecht S; Salihi R; Berteloot P; Neven P; Lambrechts D; Van Gorp T; Vergote I
Gynecol Oncol; 2022 Apr; 165(1):14-22. PubMed ID: 35177277
[TBL] [Abstract][Full Text] [Related]
17. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
Liu JF; Brady MF; Matulonis UA; Miller A; Kohn EC; Swisher EM; Cella D; Tew WP; Cloven NG; Muller CY; Bender DP; Moore RG; Michelin DP; Waggoner SE; Geller MA; Fujiwara K; D'Andre SD; Carney M; Alvarez Secord A; Moxley KM; Bookman MA
J Clin Oncol; 2022 Jul; 40(19):2138-2147. PubMed ID: 35290101
[TBL] [Abstract][Full Text] [Related]
18. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
[TBL] [Abstract][Full Text] [Related]
19. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
